| (Values in U.S. Thousands) | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 | Sep, 2022 |
| Sales | 6,300 | 7,310 | 1,240 | 6,990 | 5,780 |
| Sales Growth | -13.82% | +489.52% | -82.26% | +20.93% | +32.27% |
| Net Income | -35,320 | -12,310 | -17,410 | -7,880 | -47,570 |
| Net Income Growth | -186.92% | +29.29% | -120.94% | +83.43% | +6.58% |
Orchard Therapeutics Plc ADR (ORTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based in London, United Kingdom.
Fiscal Year End Date: 12/31